Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 May;85(1):237–247. doi: 10.1111/j.1476-5381.1985.tb08852.x

Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors.

P J Leigh, J MacDermot
PMCID: PMC1916758  PMID: 2992650

Abstract

The binding of [3H]-iloprost (ZK36374) to NCB-20 membranes revealed a single population of high affinity receptors (KD = 9.55 nM, Bmax = 431 fmol mg-1 protein) and a low affinity, non-saturable binding component. Desensitization of prostacyclin-responsiveness of NCB-20 cells is induced by culture in the presence of the stable prostacyclin analogue carbacyclin. Desensitization is accompanied by an increase in the Kact value for prostacyclin (64.1 nM to 175 nM), and a reduction in the prostacyclin-dependent increase in adenylate cyclase activity (41.2 to 15.1 pmol cyclic AMP min-1 mg-1 protein). Desensitization is not accompanied by changes in the coupling of the catalytic (C) to the regulatory (Ns) subunit of adenylate cyclase. In addition, the physical identity of the receptor molecule (as characterized by its sensitivity to electron bombardment in the beam of a linear accelerator) is not changed by desensitization. Desensitization of prostacyclin-dependent activation of adenylate cyclase may be explained most simply by a loss of prostacyclin receptors. The anomalous increase in the Kact (concentration of prostaglandin giving half-maximum enzyme activation) for prostacyclin-stimulated adenylate cyclase was not accompanied by a substantial change in the KD of [3H]-iloprost binding, and is explained by a loss of spare receptors. Prostacyclin responsiveness in non-dividing cells may be restored after desensitization by prolonged culture (up to 48 h) in the absence of carbacyclin. Resensitization is accompanied by restoration of the high affinity Kact value (143 nM to 45.5 nM), and is dependent on de novo protein synthesis.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Halim M. S., von Holst H., Meyerson B., Sachs C., Anggård E. Prostaglandin profiles in tissue and blood vessels from human brain. J Neurochem. 1980 May;34(5):1331–1333. doi: 10.1111/j.1471-4159.1980.tb09980.x. [DOI] [PubMed] [Google Scholar]
  2. Blair I. A., Hensby C. N., MacDermot J. Prostacyclin-dependent activation of adenylate cyclase in a neuronal somatic cell hybrid: prostanoid structure-activity relationships. Br J Pharmacol. 1980 Jul;69(3):519–525. doi: 10.1111/j.1476-5381.1980.tb07043.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blair I. A., Leigh P. J., MacDermot J. Desensitization of prostacyclin receptors in a neuronal hybrid cell line. Br J Pharmacol. 1982 Sep;77(1):121–127. doi: 10.1111/j.1476-5381.1982.tb09277.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blair I. A., MacDermot J. The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br J Pharmacol. 1981 Mar;72(3):435–441. doi: 10.1111/j.1476-5381.1981.tb10994.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bunting S., Gryglewski R., Moncada S., Vane J. R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins. 1976 Dec;12(6):897–913. doi: 10.1016/0090-6980(76)90125-8. [DOI] [PubMed] [Google Scholar]
  6. Dusting G. J., Moncada S., Vane J. R. Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins. 1977 Jan;13(1):3–15. doi: 10.1016/0090-6980(77)90037-5. [DOI] [PubMed] [Google Scholar]
  7. Gorman R. R., Hopkins N. K. Agonist-specific desensitization of PGI2-stimulated cyclic AMP accumulation by PGE1 in human foreskin fibroblasts. Prostaglandins. 1980 Jan;19(1):2–16. doi: 10.1016/0090-6980(80)90148-3. [DOI] [PubMed] [Google Scholar]
  8. Homburger V., Lucas M., Cantau B., Barabe J., Penit J., Bockaert J. Further evidence that desensitization of beta-adrenergic-sensitive adenylate cyclase proceeds in two steps. Modification of the coupling and loss of beta-adrenergic receptors. J Biol Chem. 1980 Nov 10;255(21):10436–10444. [PubMed] [Google Scholar]
  9. Howlett A. C. Stimulation of neuroblastoma adenylate cyclase by arachidonic acid metabolites. Mol Pharmacol. 1982 May;21(3):664–670. [PubMed] [Google Scholar]
  10. Kenimer J. G. Desensitization of PGE1 receptors in neuroblastoma-glioma hybrid cells. Prostaglandins. 1982 Mar;23(3):311–318. doi: 10.1016/0090-6980(82)90076-4. [DOI] [PubMed] [Google Scholar]
  11. Kenimer J. G., Nirenberg M. Desensitization of adenylate cyclase to prostaglandin E1 or 2-chloroadenosine. Mol Pharmacol. 1981 Nov;20(3):585–591. [PubMed] [Google Scholar]
  12. Kepner G. R., Macey R. I. Membrane enzyme systems. Molecular size determinations by radiation inactivation. Biochim Biophys Acta. 1968 Sep 17;163(2):188–203. doi: 10.1016/0005-2736(68)90097-7. [DOI] [PubMed] [Google Scholar]
  13. Koeppe P., Hamann C. A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed. 1980 Dec;12(2-3):121–128. doi: 10.1016/0010-468x(80)90058-6. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Leigh P. J., Cramp W. A., MacDermot J. Identification of the prostacyclin receptor by radiation inactivation. J Biol Chem. 1984 Oct 25;259(20):12431–12436. [PubMed] [Google Scholar]
  16. Lombroso M., Nicosia S., Paoletti R., Whittle B. J., Moncada S., Vane J. R. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Prostaglandins. 1984 Feb;27(2):321–333. doi: 10.1016/0090-6980(84)90083-2. [DOI] [PubMed] [Google Scholar]
  17. MacDermot J., Barnes P. J., Waddell K. A., Dollery C. T., Blair I. A. Prostacyclin binding to guinea pig pulmonary receptors. Eur J Pharmacol. 1981 Oct 22;75(2-3):127–130. doi: 10.1016/0014-2999(81)90071-6. [DOI] [PubMed] [Google Scholar]
  18. Miller O. V., Gorman R. R. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets. J Pharmacol Exp Ther. 1979 Jul;210(1):134–140. [PubMed] [Google Scholar]
  19. Minna J. D., Yavelow J., Coon H. G. Expression of phenotypes in hybrid somatic cells derived from the nervous system. Genetics. 1975 Jun;79 (Suppl):373–383. [PubMed] [Google Scholar]
  20. Minna J., Glazer D., Nirenberg M. Genetic dissection of neural properties using somatic cell hybrids. Nat New Biol. 1972 Feb 23;235(60):225–231. doi: 10.1038/newbio235225a0. [DOI] [PubMed] [Google Scholar]
  21. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  22. Moncada S., Herman A. G., Higgs E. A., Vane J. R. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977 Sep;11(3):323–344. doi: 10.1016/0049-3848(77)90185-2. [DOI] [PubMed] [Google Scholar]
  23. Ortmann R. Effect of PGI2 and stable endoperoxide analogues on cyclic nucleotide levels in clonal cell lines of CNS origin. FEBS Lett. 1978 Jun 15;90(2):348–352. doi: 10.1016/0014-5793(78)80402-5. [DOI] [PubMed] [Google Scholar]
  24. Pert C. B., Snyder S. H. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A. 1973 Aug;70(8):2243–2247. doi: 10.1073/pnas.70.8.2243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rodbell M. The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature. 1980 Mar 6;284(5751):17–22. doi: 10.1038/284017a0. [DOI] [PubMed] [Google Scholar]
  26. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. doi: 10.1016/0003-2697(74)90222-x. [DOI] [PubMed] [Google Scholar]
  27. Schillinger E., Prior G. Prostaglandin I2 receptors in a particulate fraction of platelets of various species. Biochem Pharmacol. 1980 Sep 1;29(17):2297–2299. doi: 10.1016/0006-2952(80)90261-0. [DOI] [PubMed] [Google Scholar]
  28. Sharma S. K., Nirenberg M., Klee W. A. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci U S A. 1975 Feb;72(2):590–594. doi: 10.1073/pnas.72.2.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shepherd G. L., Lewis P. J., Blair I. A., de Mey C., MacDermot J. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br J Clin Pharmacol. 1983 Jan;15(1):77–81. doi: 10.1111/j.1365-2125.1983.tb01467.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Siegl A. M., Smith J. B., Silver M. J., Nicolaou K. C., Ahern D. Selective binding site for [3H]prostacyclin on platelets. J Clin Invest. 1979 Feb;63(2):215–220. doi: 10.1172/JCI109292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sinzinger H., Silberbauer K., Horsch A. K., Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon? Prostaglandins. 1981 Jan;21(1):49–51. doi: 10.1016/0090-6980(81)90195-7. [DOI] [PubMed] [Google Scholar]
  32. Skuballa W., Vorbrüggen H. Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:299–305. [PubMed] [Google Scholar]
  33. Stadel J. M., De Lean A., Mullikin-Kilpatrick D., Sawyer D. D., Lefkowitz R. J. Catecholamine-induced desensitization in turkey erythrocytes: cAMP mediated impairment of high affinity agonist binding without alteration in receptor number. J Cyclic Nucleotide Res. 1981;7(1):37–47. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES